EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beta-blockers after acute coronary syndrome: insights across the ejection fraction spectrum

Eirinaios Tsiartas iD, Sokratis Oikonomou iD, Aristea Iordanidou, Athanasios Samaras iD, Andreas S Papazoglou iD, Dimitrios V Moysidis iD, Vassileios Vassilikos iD, Antonios Ziakas, Periklis Davlouros, Konstantinos Tsioufis iD, Dimitrios N Tziakas, Ioannis Zarifis iD und 1 weitere

European Heart Journal Open · 03.11.2026 · 6 (6)

DOI: 10.1093/ehjopen/oeag175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal Open, online erschienen am 14.10.2026. Verfasst von Eirinaios Tsiartas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Division, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the association between beta-blocker (BB) prescription and long-term all-cause mortality after acute coronary syndrome (ACS), and to assess whether this varies across the left ventricular ejection fraction (LVEF) spectrum. Methods and results We analysed ACS patients from the retrospective multicentre CardioMining study (NCT05176769). The primary analysis used inverse probability of treatment weighting (IPTW) and restricted mean survival time (RMST) derived from weighted Kaplan–Meier curves. RMST and survival differences were estimated at 1 and 5 years. A landmark analysis evaluated survival between years 1 and 5 among first-year survivors. Among 6049 ACS patients (age 66.8 ± 13.2 years; 74.9% male), 5107 (84.4%) were discharged on BBs. During a median 4.6-year follow-up, 1912 deaths (31.6%) occurred. Overall, the 1-year RMST difference associated with BBs was 6.3 days (95%CI 0.0 to 13.2), which attenuated further by 5 years (11.3 days, 95%CI −30.7 to 63.9). The largest 1-year RMST difference was observed among patients with LVEF ≤40% (18.8 days, 95%CI 1.1 to 37.4), whereas associations were smaller and non-significant among patients with LVEF 41–49% and LVEF ≥50%. At 5 years, confidence intervals crossed the null across all LVEF categories. Continuous LVEF analyses suggested greater short-term benefit at lower values, with progressive attenuation across the LVEF spectrum. Among 1-year survivors, no significant RMST differences were observed between years 1 and 5.

Conclusion

Discharge BB prescription was not associated with a clear long-term survival advantage after ACS in this large real-world cohort. Apparent associations were strongest at lower LVEF values and attenuated during longer follow-up.

Schlagwörter

Stichwörter der Autor:innen

Acute coronary syndromeBeta-blockerLeft ventricular ejection fractionMyocardial infarctionSecondary prevention

Autor:innen und Institutionen

  • Medical Division, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.
  • School of Medicine, Aristotle University of Thessaloniki, University Campus, Thessaloniki 541 24, Greece.
  • Second Cardiology Department, Hippokrateion University Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos, Thessaloniki 54642, Greece.
  • Department of Cardiology, Athens Naval Hospital, 70 Dinokratous, Athens 115 21, Greece.
  • Third Cardiology Department, Hippokrateion University Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos, Thessaloniki 54642, Greece.
  • First Department of Cardiology, AHEPA University Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 1 Kiriakidi, Thessaloniki 546 36, Greece.

ORCID-Profile: Eirinaios Tsiartas, Sokratis Oikonomou, Athanasios Samaras, Andreas S Papazoglou, Dimitrios V Moysidis, Vassileios Vassilikos, Konstantinos Tsioufis, Ioannis Zarifis, George Giannakoulas

Zitieren

APA

Tsiartas, E., Oikonomou, S., Iordanidou, A., Samaras, A., Papazoglou, A. S., Moysidis, D. V., Vassilikos, V., Ziakas, A., Davlouros, P., Tsioufis, K., Tziakas, D. N., Zarifis, I., & Giannakoulas, G. (2026). Beta-blockers after acute coronary syndrome: insights across the ejection fraction spectrum. European Heart Journal Open, 6(6). https://doi.org/10.1093/ehjopen/oeag175

Vancouver

Tsiartas E, Oikonomou S, Iordanidou A, Samaras A, Papazoglou AS, Moysidis DV, et al. Beta-blockers after acute coronary syndrome: insights across the ejection fraction spectrum. European Heart Journal Open. 2026;6(6). doi:10.1093/ehjopen/oeag175

BibTeX
@article{Tsiartas2026,
  author = {Tsiartas, Eirinaios and Oikonomou, Sokratis and Iordanidou, Aristea and Samaras, Athanasios and Papazoglou, Andreas S and Moysidis, Dimitrios V and Vassilikos, Vassileios and Ziakas, Antonios and Davlouros, Periklis and Tsioufis, Konstantinos and Tziakas, Dimitrios N and Zarifis, Ioannis and Giannakoulas, George},
  title = {Beta-blockers after acute coronary syndrome: insights across the ejection fraction spectrum},
  journal = {European Heart Journal Open},
  year = {2026},
  volume = {6},
  number = {6},
  doi = {10.1093/ehjopen/oeag175}
}
Kostenlos starten →